Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The microbial cell membranes and cell walls of Streptococcus mutans and Candida albicans are critical structural components that facilitate the formation of virulent cross-kingdom biofilms in the oral cavity. Streptococcus mutans, a primary cariogenic bacterium, relies on its peptidoglycan-rich cell wall and extracellular glucans for tooth adherence and acid tolerance (PMID: 25135932). Candida albicans, an opportunistic fungal pathogen, possesses a complex cell wall composed of chitin, beta-glucans, and mannans, as well as a cell membrane containing ergosterol, which are vital for its structural integrity and transition between yeast and hyphal forms (PMID: 31151103). These two organisms interact synergistically; for instance, S. mutans-derived glucosyltransferases (GtfB) bind to the C. albicans cell wall, promoting the assembly of a dense, sugar-rich extracellular matrix that protects the microbes from antimicrobial agents (PMID: 24532137). Therapeutic interventions often target these structures using agents like polyenes (e.g., Amphotericin B) to disrupt fungal membranes, echinocandins to inhibit fungal cell wall synthesis, or chlorhexidine to compromise bacterial and fungal cell envelopes (PMID: 28943461). Effective targeting of these components is essential for treating dental caries and oral candidiasis, though the physical barrier of the biofilm and potential toxicity to human mucosal cells remain significant therapeutic challenges (PMID: 30258110).
Drugs targeting these structures act by disrupting the physical integrity of the lipid bilayer (e.g., polyenes binding to ergosterol), inhibiting the biosynthesis of essential structural polymers like peptidoglycan in bacteria or beta-glucans and chitin in fungi, or interfering with the enzymatic production of extracellular polysaccharides that glue the organisms together (PMID: 28943461, PMID: 25135932).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Microbial cell membranes and cell walls of Streptococcus mutans and Candida albicans.